DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0202709 A1 Kirby Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0202709 A1 Kirby Et Al US 2004O2O2709A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0202709 A1 Kirby et al. (43) Pub. Date: Oct. 14, 2004 (54) COMPOSITIONS FOR RAPID AND (60) Provisional application No. 60/091,910, filed on Jul. NON-IRRITATING TRANSIDERMAL 7, 1998. DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR Publication Classification FORMULATING SUCH COMPOSITIONS AND DELIVERY THEROF (51) Int. Cl. ................................................... A61K 9/70 (52) U.S. Cl. .............................................................. 424/449 (76) Inventors: Kenneth B. Kirby, Lake Park, FL (US); Berno Pettersson, Perry, GA (57) ABSTRACT (US) A transdermal delivery system (TDS)for use in treatment of Correspondence Address: living bodies may be applied as an open (liquid, gel) or MCHALE & SLAVIN, PA. closed (patch) article. The TDS is composed of a particular 2855 PGA BLVD active agent which dictates an associated Selection of certain PALM BEACH GARDENS, FL 33410 (US) Solvents, Solvent modifiers, Solute modifiers and skin Stabi lizers with which the medicament forms a true Solution that (21) Appl. No.: 10/831,416 rapidly crosses the skin barrier. The associated Selection of (22) Filed: Apr. 23, 2004 the particular Solvents, Solvent modifiers, Solute modifiers and Skin Stabilizers is based on a balancing of the molecular Related U.S. Application Data properties of all the components against the molecular properties of all the components plus the particular active (62) Division of application No. 10/074,497, filed on Feb. agent. The TDS may also include a Source of cellular energy 11, 2002, which is a division of application No. to induce CAMP or cGMP. The TDS improves delivery of 09/381,095, filed on May 11, 2000, now Pat. No. active agents having a molecular weight greater than 340 6,444,234, filed as 371 of international application Daltons and increases dosage above 0.25 mg/day for Such No. PCT/US99/15297, filed on Jul. 7, 1999. active agents. Patent Application Publication Oct. 14, 2004 Sheet 1 of 4 US 2004/0202709 A1 .H O) E 4 O O O O O O O O e n CN r (uo/bri) pea eeulled aunouri Patent Application Publication Oct. 14, 2004 Sheet 2 of 4 US 2004/0202709 A1 s 3. s (uo/frt) peae euated quinouri Patent Application Publication Oct. 14, 2004 Sheet 3 of 4 US 2004/0202709 A1 i O O O S 3 usO (uo/bri) peae euced unouri Patent Application Publication Oct. 14, 2004 Sheet 4 of 4 US 2004/0202709 A1 s O O N s (uo/frt) pea eeuded runouri US 2004/0202709 A1 Oct. 14, 2004 COMPOSITIONS FOR RAPID AND 0010 With regard to the molecular weight limitations, NON-IRRITATING TRANSIDERMAL DELIVERY OF currently commercially available TDD systems deliver mol PHARMACEUTICALLY ACTIVE AGENTS AND ecules with molecular weights less than about 340 D and in METHODS FOR FORMULATING SUCH amounts generally less than about 1.0 mg per 24 hours. COMPOSITIONS AND DELIVERY THEROF 0011 Additionally, candidate medicaments should also, RELATED APPLICATIONS preferably, be Soluble in ethanol and/or isopropanol and/or glycols or dimethyl sulfoxide (DMSO) and should not be 0001) This application is a division of Ser. No. 10/074, chemically altered by solubilization. Another potentially 497, filed Feb. 11, 2002 and now U.S. Pat. No. s limiting factor is for compounds which can have efficacy at which is a division of Ser. No. 09/381,095, filed May 11, relatively Small doses introduced Systemically via the cap 2000, now U.S. Pat. No. 6,444,234 issued Sep. 3, 2002 which is a sec. 371 application of PCT/US/99/15297, filed illary net of the dermis. Main limiting factors thus include Jul. 7, 1999 which claims priority to Provisional Application molecule size and irritation potential of the medicament plus 60/091,910, filed Jul. 7, 1998. Solvent(s) and other components. 0012. The inventors have also analyzed the chemistry and FILED OF THE INVENTION chemical Structures of active ingredients and carriers of 0002 This invention relates to transdermal delivery of transdermal delivery Systems and have found other limiting active agents, including pharmaceuticals, cosmetics, nutri factors leading to the limited Success of transdermal drug ents, and the like, across the skin barrier of humans or other delivery. Most typically it has been observed that these animals and to a method for developing new transdermal Systems have not been widely acceptable because the drug delivery Systems for any particular polar or non-polar active carriers chemically bound with the medicament resulting in agent of Small or large molecular Size, which delivery non-bioavailable compounds transmigrating the skin; or/and Systems are capable of rapidly delivering the active agent to the carrier, e.g., DMSO, reduces the medicament yielding a a targeted location Systemically or locally. non-bioavailable or non-bio-equivalent compound or creates toxic by-products of transmigration. BACKGROUND OF THE INVENTION 0013 Only about 1% or less of known medicaments 0003. The pharmaceutical industry is actively seeking to would not be excluded for administration by a TDD System develop new and improved modes of drug delivery to based on the above limiting factors. Still further, TDD enhance the effectiveness of particular drugs, including, Systems currently available are usually Subject to broadly targeting the drug to the intended site, reducing dosage, varying results as a function of the circulation efficiency of decreasing toxicity, and the like. Major efforts are underway the patient. Age, size and weight of the patient all impact in molecule Stabilization for parenteral applications, how efficiently these systems perform. For most TDD sys extended release modalities for enteral drugs and photacti tems there is virtually no drug penetration for the first hour Vated chemotherapeutic molecules, for example. Delivery of after application and often 24 to 48 hours are required to medications via transdermal drug delivery (TDD) systems achieve a therapeutic level. (patches) has also seen dramatic developments, see U.S. Pat. Nos. 4,879,275; 3,996,934; and 3,731,683. For example, it 0014. The anatomy and physiology of the integument is now generally agreed that chemical modification of the was analyzed to understand the complex protective mecha barrier properties of the Skin is a Safe and effective method nism of physical, biochemical and bio-electrical gradients to enhance penetration of medicaments (Ref. 1). However, which work to minimize the penetration of foreign Sub to Some extent it seems that this mode of delivery has stances and Sensitize the organism to react more rapidly and reached its technological limits. aggressively to future exposures. As a result of this analysis it is postulated that: 0004) The present inventors have analyzed the TDD Systems and have been able to identify certain limiting 0015 The primary pathway of transdermally deliv factors. These include, for example, limitations to com ered drugs is paracellular, i.e., around the cells, then pounds which are through the elastin glue. 0005) lipophilic medicaments, 0016. The glue-like compound, elastin, composed of collagen and hyaluronic acid and other lipids, which 0006 medicaments with an effective therapeutic occupies the interstices between the cells of the dose of less than 1 mg per day; top-most layer of the skin (i.e., the epidermis, includ ing, e.g., Stratum corneum (SC), lucidum, granulo 0007 medicaments having a melting point below Sum, Spinosus) must be dissolved (or otherwise about 150° C.; disrupted) in order for a medicament or other active 0008 medicaments having molecular weight of agent, dissolved in a Solvent, to transmigrate through from less than about 300 to about 500 Daltons (the viable skin (VS) to the subcutaneous tissues where larger the molecule, the leSS is the amount deliver the cutaneous plexi of the capillary net can be able via the stratum corneum); reached and/or deeper penetration achieved (Ref. 2). When the elastin is dissolved, other agents may then 0009 molecules which do not elicit a rapidly cas transmigrate the Outer layers, So the body immedi cading immune response when transmigrating the ately begins to attempt to repair the damage caused skin. by the dissolution. US 2004/0202709 A1 Oct. 14, 2004 0017 Skin penetration enhances (SPE) which deli 0026. Transient increases in cutaneous blood flows pidize can reduce the barrier capacity of the SC as a may result in increased Systemic absorption of the function of Species of enhancer and its concentration. drug from the depot of the TDD (Ref. 5). Permeability may often be adjusted by modifying the 0027) Furthermore, cellular biological issues were HLB of the enhancer (Ref. 3). reviewed in order to identify and categorize membrane and 0018 Capilary circulation acts as a sink for the organelle functions, both in the integument and in other medicament, thus maintaining a steep chemical tissues, which might be Subject to variations which might potential gradient across the skin (Ref. 4). help or hinder tissue transmigration of a medicament and Solvent. In particular, it is proposed that, 0019. Diffusivity of a drug molecule is dependent on 0028 SPE's and solvent modification systems can properties of both the medicament and the medium cause irritation apart from the medicament they are (carrier). The diffusivity in liquid media, in general, delivering. Chronic exposure to irritants has the tends to decrease with increased molecular volume potential to become carcinogenic and, therefore, care (Ref. 5). must be taken in the design and testing of TDD 0020. The rate of skin penetration is a function of (1) Systems. the Diffusion Coefficient, (2) the barrier partitioning 0029 Efferent tactile corpuscles of nerves form an tendencies, (3) binding affinities, and (4) the rate of “early warning detection System.” The cellular and metabolism of the medicament by the skin (Ref.
Load more

Recommended publications
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI Chemical Activity Count (+)-AROMOLINE 1 (+)-CATECHIN 5 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 1 (+)-PRAERUPTORUM-A 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (-)-ACETOXYCOLLININ 1 (-)-APOGLAZIOVINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-CANADINE 1 (-)-EPICATECHIN 4 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 1 (-)-EPIGALLOCATECHIN-3-O-GALLATE 2 (-)-EPIGALLOCATECHIN-GALLATE 3 (-)-HYDROXYJASMONIC-ACID 1 (-)-N-(1'-DEOXY-1'-D-FRUCTOPYRANOSYL)-S-ALLYL-L-CYSTEINE-SULFOXIDE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 Chemical Activity Count 1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)-1,6-HEPTADIEN-3,5-DIONE 1 1,8-CINEOLE 1 1-(METHYLSULFINYL)-PROPYL-METHYL-DISULFIDE 1 1-ETHYL-BETA-CARBOLINE 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 10-GINGEROL 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 14-ACETOXYCEDROL 1 14-O-ACETYL-ACOVENIDOSE-C 1 16-HYDROXY-4,4,10,13-TETRAMETHYL-17-(4-METHYL-PENTYL)-HEXADECAHYDRO- 1 CYCLOPENTA[A]PHENANTHREN-3-ONE 2,3,7-TRIHYDROXY-5-(3,4-DIHYDROXY-E-STYRYL)-6,7,8,9-TETRAHYDRO-5H-
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction
    pharmaceutics Review Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction Maria D. Auxtero 1, Susana Chalante 1,Mário R. Abade 1 , Rui Jorge 1,2,3 and Ana I. Fernandes 1,* 1 CiiEM, Interdisciplinary Research Centre Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal; [email protected] (M.D.A.); [email protected] (S.C.); [email protected] (M.R.A.); [email protected] (R.J.) 2 Polytechnic Institute of Santarém, School of Agriculture, Quinta do Galinheiro, 2001-904 Santarém, Portugal 3 CIEQV, Life Quality Research Centre, IPSantarém/IPLeiria, Avenida Dr. Mário Soares, 110, 2040-413 Rio Maior, Portugal * Correspondence: [email protected]; Tel.: +35-12-1294-6823 Abstract: Late-life mild cognitive impairment and dementia represent a significant burden on health- care systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treat- ment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmaco- logical interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • WO 2007/123699 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 1 November 2007 (01.11.2007) PCT WO 2007/123699 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (21) International Application Number: CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, PCT/US2007/007935 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, (22) International Filing Date: 29 March 2007 (29.03.2007) IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, (25) Filing Language: English MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, (26) Publication Language: English RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (30) Priority Data: 60/787,552 30 March 2006 (30.03.2006) US (84) Designated States (unless otherwise indicated, for every 60/841,739 1 September 2006 (01.09.2006) US kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, DANA-FARBER CANCER INSTITUTE, INC. ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), [US/US]; 44 Binney Street, Boston, MA 021 15 (US).
    [Show full text]
  • Study Protocol
    CLINICAL STUDY PROTOCOL A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure NCT Number: NCT03772041 PRT NO.: 263-102-00003 Version Date: 27 March 2020 (Version 3.0) Otsuka Pharmaceutical Co., Ltd. Investigational Medicinal Product OPC-61815 CLINICAL PROTOCOL A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure Protocol No. 263-102-00003 CONFIDENTIAL – PROPRIETARY INFORMATION Clinical Development Phase: 3 Sponsor: Otsuka Pharmaceutical Co., Ltd. Immediately Reportable Event Otsuka Pharmaceutical Co., Ltd. Department of Pharmacovigilance Email: [email protected] Amendment 2 Approval: 27 Mar 2020 Amendment 1 Approval: 15 Mar 2019 Approval: 26 Sep 2018 Date of Translation: 9 Jun 2020 Protocol 263-102-00003 Protocol Synopsis Name of Sponsor: Otsuka Pharmaceutical Co., Ltd. Protocol No.: 263-102-00003 Name of Investigational Medicinal Product: OPC-61815 Protocol Title: A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure Clinical Phase/Trial Phase 3/Confirmatory Trial Type: Treatment Indication:
    [Show full text]
  • Transcriptional Response Networks for Elucidating Mechanisms of Action Of
    Drug Discovery Today Volume 21, Number 7 July 2016 REVIEWS Systems-level drug response phenotypes combined with network models offer an exciting means for elucidating the mechanisms of action of polypharmacological agents, including multitargeted natural products. Transcriptional response networks for FOUNDATION REVIEW elucidating mechanisms of action of multitargeted agents Reviews 1 1 2 Milla Kibble received her Milla Kibble , Suleiman A. Khan , Niina Saarinen , PhD in pure mathematics 3 3,4 2 from University College Francesco Iorio , Julio Saez-Rodriguez , Sari Ma¨kela¨ and London in 2000. She 1,5 subsequently worked at Tero Aittokallio Numbercraft Ltd., using analytics techniques to gain 1 Institute for Molecular Medicine Finland (FIMM), Biomedicum Helsinki 2U, Tukholmankatu 8, University of information from large data sets. Since then, she has Helsinki, Helsinki 00014, Finland 2 combined teaching of mathematics and statistics with Institute of Biomedicine, Turku Center for Disease Modeling & Functional Foods Forum, University of Turku, Turku research into probability and graph theory applications 20014, Finland to biological data in the Biomathematics Group at 3 European Molecular Biology Laboratory – European Bioinformatics Institute, Wellcome Trust Genome Campus, Turku University and the Stochastics Group at Aalto Cambridge CB10 1SD, UK University. Milla joined the Institute for Molecular 4 Medicine Finland (FIMM) as a senior researcher in 2014 Joint Research Centre for Computational Biomedicine (JRC-COMBINE) – RWTH Aachen University, Faculty of and her research focuses on network pharmacology Medicine, D-52074 Aachen, Germany 5 approaches to elucidate mechanisms of action and Department of Mathematics and Statistics, Quantum, University of Turku, Turku 20014, Finland efficacy of drugs and their combinations, with a particular interest in natural products.
    [Show full text]